Aims: The aim of this study was to evaluate the efficacy and safety of 24-month vs. six-month dual antiplatelet therapy (DAPT) among elderly (≥75 years) and non-elderly patients (<75 years) undergoing percutaneous coronary intervention.
Introduction
Elderly individuals account for an increasing proportion of patients with coronary artery disease undergoing percutaneous coronary intervention (PCI), due to the ageing of the population with increased life expectancy [1] [2] [3] . Dual antiplatelet therapy (DAPT) with aspirin and oral P2Y 12 adenosine diphosphate receptor inhibitors represents the standard of treatment to prevent new atherothrombotic events after PCI, yet its optimal duration remains controversial [4] [5] [6] . Results from randomised trials and meta-analyses indicate that extended (i.e., >12 months) duration of DAPT is associated with a lower risk of ischaemic events, even though this benefit is partly offset by a higher risk of clinically relevant bleeding [7] [8] [9] . However, extrapolating such findings to elderly patients is challenging in view of the increased risk of bleeding and ischaemic events occurring in this subgroup. In addition, elderly individuals have been underrepresented among randomised trials that evaluated different durations of DAPT following PCI. The Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) compared a strategy of DAPT extended to 24 months with a shorter course of DAPT up to six months in a broadly inclusive population of PCI patients, with the inclusion of a relatively high proportion of elderly participants 10 .
Therefore, we sought to evaluate the impact of age in modulating the hazard of ischaemic and bleeding events and to investigate the outcomes of 24-month vs. six-month DAPT in elderly (≥75 years) vs. younger patients (<75 years) enrolled in the PRODIGY trial.
Methods
Details on study design and primary results of the PRODIGY trial have been reported elsewhere 10 . Briefly, all-comer patients undergoing treatment with a balanced mixture of stents were randomly allocated at 30 days to either up to six months or to 24 months of DAPT. The ethics committees of the participating centres independently approved the protocol and all participants gave written informed consent.
TREATMENT PROTOCOL
All patients received aspirin (80-160 mg orally indefinitely) and clopidogrel (75 mg/day) according to the randomisation scheme as follows: for either up to six months in the short DAPT group or to 24 months in the prolonged DAPT arm, irrespective of the previously implanted stent type or indication for PCI.
STUDY ENDPOINTS
The primary efficacy endpoint of the PRODIGY trial was the composite of death, myocardial infarction (MI), or cerebrovascular accident (CVA), whereas the key safety endpoint included Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. Other endpoints included each component of the primary efficacy endpoint, cardiovascular death, stent thrombosis defined on the basis of the Academic Research Consortium criteria, and BARC type 3 or 5 bleeding. Additional safety endpoints were bleeding events adjudicated according to the Thrombolysis In Myocardial Infarction (TIMI) and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. More detailed definitions of the endpoints have been provided previously 11 . A clinical events committee blinded to treatment allocation adjudicated all efficacy and bleeding events.
STATISTICAL ANALYSIS
Continuous variables are presented as mean±standard deviation and were compared with the Wilcoxon rank-sum test. Categorical variables are expressed as counts and percentages and were compared with chi-square or Fisher's exact tests as appropriate. We evaluated the effect of age, modulated as a continuous variable, on the risk of ischaemic and bleeding events in the overall population by means of multivariable-adjusted, restricted cubic splines with three knots of the distribution (10 th , 50 th , and 90 th percentiles) 12 . The effect of age on clinical events was analysed in the categories of patients <75 vs. ≥75 years by using Cox regression analyses. Both analyses were adjusted for baseline clinical variables associated with the primary efficacy and key safety endpoints at the univariate analysis with a significance level of p<0.20. The efficacy and safety of 24-month DAPT vs. six-month DAPT for elderly (≥75 years) vs. non-elderly (<75 years) patients was evaluated at 24 months. Clinical events were expressed as counts with rates computed according to the Kaplan-Meier method. Cox regression analysis was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) and an interaction test was provided to evaluate the effect of treatment in the elderly vs. non-elderly. Sensitivity analyses were conducted to evaluate the efficacy and safety of DAPT from six to 24 months by using a landmark analysis and to assess whether results were consistent by applying the cut-off of 65 years to define the elderly status. In addition, we evaluated the risk of deaths associated or not with MI if they occurred within a sevenday window from MI onset. Risk difference and the number needed to treat for benefit or harm (NNTB or NNTH) with relative 95% CI were also provided in order to account for absolute risk estimates. Finally, the interaction between treatment effect and ageing, modelled as a continuous variable, was analysed with a fractional polynomial interaction 13 . All p-values are two-sided and statistical significance was assumed for p<0.05. All analyses were carried out with Stata Statistical Software, Release 13 (StataCorp LP, College Station, TX, USA).
Results
Of 1,970 participants enrolled in the PRODIGY trial, 587 (29.8%) patients were ≥75 years of age and 1,383 (70.2%) patients were <75 years of age. As shown in Table 1 and Table 2 , baseline and periprocedural features were largely comparable within the elderly vs. non-elderly groups between patients assigned to 24-month or six-month DAPT.
EFFECT OF AGEING ON CLINICAL OUTCOMES
There was a direct graded relationship between age and the risks of the primary efficacy or the key safety endpoint, with a steeper increase in the hazard trajectories beyond 70 years of age ( Figure 1) . A similar direct association between age and bleeding events was observed for BARC type 3 or 5, TIMI minor or major, or GUSTO moderate or severe bleeding (data not shown). When dichotomised, patients with age ≥75 years compared with younger participants had a higher risk of death, MI or CVA and BARC type 2, 3 or 5 bleeding. Figure 2A shows the analysis of efficacy endpoints at two-year follow-up. There was a significant interaction (p=0.036) between Figure 2B) . By using a cut-off of 65 years, there was no significant interaction (p=0.09) with 24-month vs. six-month DAPT with respect to the primary ischaemic endpoint among patients ≥65 years (HR 0.89, 95% CI: 0.66-1.21, p=0.48) vs. those <65 years (HR 1.75, 95% CI: 0.86-3.58, p=0.13). Figure 3A shows the analysis of safety endpoints at two-year followup. BARC type 2, 3 or 5 bleeding was significantly increased in both elderly (HR 1.90, 95% CI: 
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INTERACTION BETWEEN AGEING AND TREATMENT EFFECT OF DAPT
The age-by-treatment interaction evaluated by fractional polynomial analyses was not significant for the primary efficacy (p=0.35)
and key safety endpoints (p=0.73). For the composite of death, MI or CVA, the area representing the 95% CI treatment effect crossed the no effect line throughout all ages ( Figure 4A) . In contrast, the area of treatment effect for the key safety endpoint was above the line of no effect for a wide range of ages, indicating a harmful effect of 24-month over six-month DAPT in terms of bleeding complications for most age values ( Figure 4B ).
Discussion
The main findings of the present analysis of the PRODIGY trial can be summarised as follows. 1) Elderly patients undergoing PCI have a higher risk of ischaemic and bleeding events compared with younger patients, with a similar effect of ageing on the hazards of such events. 2) In both elderly and non-elderly patients, prolonging DAPT for 24 months did not reduce the risk of the primary efficacy endpoint of death, MI or CVA compared with a six-month DAPT. 3) A strategy of 24-month DAPT compared with six-month DAPT was associated with a greater risk of the key safety endpoint of BARC type 2, 3 or 5 bleeding in both elderly and nonelderly patients. Although the relative magnitude of treatment effect on bleeding was similar, the absolute risk difference with prolonged DAPT was greater in elderly compared with younger participants.
DAPT is an evidence-based, guideline-recommended, standard of care treatment after PCI 14 . Recently, two large randomised trials, DAPT and PEGASUS-TIMI 54 (Prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54), showed a significant reduction in ischaemic events with long-term DAPT among patients undergoing PCI as well as among high-risk patients with prior myocardial infarction 7, 9, 15, 16 . Nevertheless, the optimal treatment duration of DAPT remains controversial as the protection afforded by extended DAPT in terms of ischaemic events is counterbalanced by an increase in bleeding complications 7, 8 . Although the PEGASUS-TIMI 54 trial reported consistent results in terms of the primary ischaemic endpoint according to age, elderly patients represented less than 15% of the overall population 15 . However, despite being formally not significant (p for interaction=0.09), elderly versus non-elderly patients derived less ischaemic benefit from 90 mg of ticagrelor vs. placebo. At variance, among participants allocated to ticagrelor 60 mg, elderly patients derived a similar magnitude of benefit to non-elderly patients with regard to the primary efficacy endpoint. A treatment-by-age heterogeneity for the primary endpoint according to age has been observed in the ISAR-SAFE (p for interaction=0.03) and IVUS-XPL trials (p for interaction=0.051), favouring the use of short-term DAPT in elderly rather than younger patients 17, 18 . However, the primary endpoint in both trials included a composite of ischaemic and bleeding events, which did not allow complete assessment of the benefit-risk ratio associated with DAPT in elderly patients.
We found that elderly patients experienced a greater risk of both ischaemic and bleeding events, with risk trajectories proceeding similarly with ageing. Such a pattern is similar to that described by Roe and colleagues in a cohort of patients with acute coronary syndrome managed without revascularisation 19 . Prolonged DAPT did not reduce the risk of ischaemic events among both elderly and non-elderly patients, which is in keeping with the results in the overall finding of the PRODIGY trial. However, interaction testing showed heterogeneity in treatment effect for the primary efficacy endpoint, with a possible harmful effect with 24-month DAPT in non-elderly subjects. In this regard, the higher risk of cardiac instead of non-cardiac death among younger patients randomised to 24-month DAPT, although not related to MI, remains biologically counterintuitive and difficult to explain. Such a finding could also be the result of variable categorisation rather than a direct effect, because the age-by-treatment interaction on a continuous basis was not significant at the fractional polynomial analysis.
Our study provides a nuanced interpretation for the alleged difference in the risk of bleeding associated with DAPT use among elderly patients. We found that prolonged DAPT had a similar effect on the key bleeding endpoint of BARC type 2, 3 or 5 among elderly and non-elderly patients at 24-month follow-up. However, owing to the higher rate of bleeding events, elderly patients had a greater increase in the absolute risk of BARC 2, 3 or 5 bleeding with 24-month DAPT, resulting in a lower NNTH (18 vs. 29). During the period between six and 24 months, the absolute risk difference in BARC 2, 3 or 5 bleeding tended to increase, as well as the difference in the NNTH (18 vs. 36). Taken together, these findings suggest that relative and absolute risks of bleeding should be disentangled in the decision process for DAPT duration in elderly people, by factoring the similar relative risk of bleeding associated with prolonged DAPT with the higher absolute risk difference due to the increased event rate.
Limitations
The results of this study have to be interpreted in the light of several limitations. First, our observations are based on subgroup populations within an overall trial, which failed to show the superiority of prolonged DAPT in the main population. Second, although there is general agreement that people ≥75 years can be defined as "elderly", ageing is a continuous process and the cut-off of 75 years remains arbitrary. Nevertheless, we tried to accommodate this limitation by evaluating the age-by-treatment interaction also on a continuous basis. Furthermore, a cut-off of 65 years yielded similar results. Third, the group of elderly patients was relatively modest in size, and all the analyses should be considered as hypothesis-generating and exploratory in nature. However, it is noteworthy that the mean age in the PRODIGY trial was the highest across available trials with comparable design. This might explain the differential effect of elderly status on the risk of ischaemic events observed in this study compared with other trials enrolling relatively younger patients. Fourth, randomisation in the PRODIGY trial was not stratified by age.
Conclusions
In an all-comers population of PCI patients, elderly participants experienced a higher risk of ischaemic and bleeding events compared with their non-elderly counterparts with a comparable effect of ageing on the hazards of such events. Prolonging DAPT for 24 months was not associated with a significantly different risk of the primary efficacy endpoint among elderly and non-elderly patients. However, elderly patients seemed to derive a greater absolute risk of clinically relevant bleeding from prolonged DAPT than younger patients.
Impact on daily practice
Elderly status conveys a higher risk of both ischaemic and bleeding events. Although dual antiplatelet therapy increases the risk of bleeding in both elderly and non-elderly patients, the former group incurs a substantially higher event rate. The efficacy of prolonged dual antiplatelet therapy for the prevention of ischaemic events is not influenced by elderly status. 
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